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Infants born more than 8-10 weeks preterm are at risk of developing sight-threatening retinopathy 43 
of prematurity (ROP). In the UK and other countries, paediatric ophthalmologists systematically 44 
screen infants at risk, with the aim of identifying ROP requiring treatment to prevent adverse 45 
structural outcomes such as retinal detachment and macular dragging, and poor functional 46 
outcomes such as sight impairment. 47 
ROP screening involves instillation of mydriatics, application of a lid speculum, and fundoscopy via 48 
indirect ophthalmoscopy or digital imaging, and is distressing for infants. Changes in blood pressure, 49 
respiratory rate, oxygen saturation and pulse rate and facial changes indicative of pain are common. 50 
1 2 3 Repeated screening is required at weekly or two-weekly intervals either until ROP has 51 
spontaneously regressed, or a need for treatment has been established. 52 
 53 
ROP screening requires a skilled workforce available 52 weeks a year. Failure to identify infants 54 
requiring treatment at the appropriate time, as well as resulting in blindness for the premature 55 
infant, can have significant adverse medicolegal considerations. 4 Over recent years, the increasing 56 
number of infants surviving preterm birth has resulted in an increased need for trained paediatric 57 
ophthalmologists.  58 
 59 
There is no universal consensus on the cut-off for gestational age (GA) that should determine the 60 
need for screening, and as ROP is a developmental disorder it is illogical for birth weight (BW) to be 61 
included in the selection algorithm. The inclusion of BW likely arose before universal assignment of 62 
GA through early ultrasound assessment, and remains a historical anachronism. In the US, screening 63 
is recommended for GA of 30 weeks or less and BW of 1,500g or less (plus selected infants with a 64 
higher GA and BW and an unstable clinical course). 5 In Canada, infants are screened if GA is 30+6/7 65 
or less, regardless of BW, or if BW is 1,250g or less. 6 In Sweden, screening is undertaken for GA of 31 66 
weeks or less, with no consideration of BW. 7 67 
 4 
The current UK guidelines (2008) recommend screening for infants with a GA of less than 32 weeks 68 
or BW less than 1,501 g. 8 We recently reported that of 8,112 infants with BW less than 1,500g born 69 
over a one-year period in the UK and Northern Ireland, 327 (4%) required ROP treatment. 9 A 70 
revision of the UK ROP screening guidelines is now under consideration.  71 
Is it possible to reduce the UK screening burden? 72 
In our recent national study, the median GA of infants requiring ROP treatment was 25 weeks and 73 
the median BW 706 g. 9 No baby was over 32 weeks GA and all were 31 weeks GA or less; only one 74 
baby had a BW over 1,500 g (BW 2,080g, GA 30+1 weeks, diabetic mother). 75 
 76 
Tightening the UK screening criteria to reduce the number of infants screened unnecessarily should 77 
ensure that no cases of ROP requiring treatment are missed. Possible scenarios are to 1) keep the 78 
current GA indication of 31+6 weeks whilst lowering the BW cutoff to less than 1,251g, 2) lower the 79 
GA cutoff to 30+6 weeks whilst keeping a BW of less than 1,501g, or 3) lower both GA and BW cutoff 80 
(GA of 30+6 and birth weight of less than 1,251g), 4) use GA only of 31+6 or less, 5) use GA only of 81 
30+6 or less. 82 
With information provided by the Neonatal Data Analysis Unit (NDAU) from the National Neonatal 83 
Research Database we examined the effect any changes in screening criteria would have on the 84 
number of babies undergoing screening. The data covers the same time period as the national 85 
treatment study. 86 
The first option would reduce the number of infants screened by 1,071 babies or 11.1%, the second 87 
by 12.6% (1,210 babies), the third by 28.9% (2,790 babies), the fourth by 14.7% (1,414 babies), and 88 
the fifth by 35.5% (3,421 babies) (Table 1). Options 1, 2 and 4 would have included all infants 89 
requiring treatment in the national treatment study cohort. Option 3 would have missed one infant 90 
 5 
who required treatment (GA 31+0 weeks, BW 1,400g) and narrowly included another (GA 30+6 91 
weeks, BW 1,480g), and option 5 would have missed the baby of 31+0 weeks GA.  92 
A previous report from the NDAU has cautioned that reducing the screening criteria to <31 weeks 93 
GA or BW<1251g (scenario 3) would over a three-year period from 2009 to 2011 have missed 8 94 
babies requiring treatment. 10 95 
Based on these figures, it appears safe to tighten the UK ROP screening guidelines to include infants 96 
with a GA of 31+6 weeks or less or BW less than 1,251g (scenario 1), or those with GA of 30+6 weeks 97 
or BW less than 1,501g (scenario 2). It would not be safe to lower both GA and BW cutoffs (scenario 98 
3). Alternatively, an age only inclusion criteria could be used which, based on our data, would need 99 
to be 31+6 or less (scenario 4).  The risk of only using GA as an inclusion criteria is that occasionally 100 
infants born at over 32 weeks GA may have a very low BW due to growth restriction.  However the 101 
effect of growth restriction as an independent risk factor for ROP is unknown.  Although uncertain 102 
GA was an important consideration in an earlier age, in well-developed healthcare systems with 103 
good obstetric care and ultrasound dating, this is now an unusual event.  104 
Tightening the guidelines would spare 11 to 14.7% of infants the distress of repeated screening 105 
assessments, and reduce the economic burden of screening to the NHS. 106 
We suggest that further prospective research  analysing  screening and treatment data from both 107 
ophthalmology and neonatal sources might allow further refinement in guidelines. 108 
 109 
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 111 
          Potential reduction in infants screened (%) 
  England Scotland Wales Total England Scotland Wales Total  
 Number of infants with BW fulfilling current UK screening guidelines     
GA 31+6 weeks or less OR 
BW less than 1,501g 8767 503 368 9638         
Number of infants to be screened if guidelines tightened 
   
GA 31+6 weeks or less OR 
BW less than 1,251g 7783 457 327 8567 11.2 9.1 11.1 11.1 
GA 30+6 weeks or less OR 
BW less than 1,501g 7683 439 306 8428 12.4 12.7 16.8 12.6 
GA 30+6 weeks or less OR 
BW less than 1,251g 6243 360 245 6848 28.8 28.4 33.4 28.9 
GA 31+6        7474 439     311 8224        14.7           12.7     15.4    14.7 
GA 30+6 
          
5672 333   212 6217 35.3  33.8 42.4 35.5 
 112 
Table 1. Data on infants recorded in the National Neonatal Research Database (birth dates 1 113 
December 2013 – 30 November 2014) and potential reduction in infants screened for ROP if UK 114 
screening guidelines tightened. 115 
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